Login to Your Account



Santaris, Shire Ink $380M+ Deal for Rare Generic Disorder Drugs

By Donna Young


Wednesday, August 26, 2009
Danish firm Santaris Pharma AS racked up another multimillion dollar deal to develop drugs based on its locked nucleic acid (LNA) platform targeting microRNAs and messenger RNAs, this time with London-based Shire plc for drugs to treat rare genetic disorders. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription